165 related articles for article (PubMed ID: 35461769)
1. Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation.
Park YE; Park SY; Jhun BW; Park Y; Kang YA; Park J; Kwak N; Yim JJ; Shim TS; Jo KW
J Infect Chemother; 2022 Aug; 28(8):1098-1104. PubMed ID: 35461769
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.
Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N
BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Intermittent Multidrug IV Therapy for Refractory Mycobacterium abscessus Pulmonary Disease.
Im Y; Kim SY; Kim DH; Jhun BW
Chest; 2024 Feb; 165(2):288-302. PubMed ID: 37661004
[TBL] [Abstract][Full Text] [Related]
5. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease.
Kim SR; Jang M; Kim SY; Kim DH; Jhun BW
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0077422. PubMed ID: 36165626
[TBL] [Abstract][Full Text] [Related]
7. Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of
Park Y; Park YE; Jhun BW; Park J; Kwak N; Jo KW; Yim JJ; Shim TS; Kang YA
Open Forum Infect Dis; 2021 Jun; 8(6):ofab215. PubMed ID: 34189168
[TBL] [Abstract][Full Text] [Related]
8. An Intensified Regimen Containing Linezolid Could Improve Treatment Response in
Li H; Tong L; Wang J; Liang Q; Zhang Y; Chu N; Chen X; Duan H
Biomed Res Int; 2019; 2019():8631563. PubMed ID: 31828137
[TBL] [Abstract][Full Text] [Related]
9.
Kwak N; Dalcolmo MP; Daley CL; Eather G; Gayoso R; Hasegawa N; Jhun BW; Koh WJ; Namkoong H; Park J; Thomson R; van Ingen J; Zweijpfenning SMH; Yim JJ
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 30880280
[TBL] [Abstract][Full Text] [Related]
10. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
[TBL] [Abstract][Full Text] [Related]
12. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Mycobacterium abscessus Pulmonary Disease.
Griffith DE; Daley CL
Chest; 2022 Jan; 161(1):64-75. PubMed ID: 34314673
[TBL] [Abstract][Full Text] [Related]
14. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
[No Abstract] [Full Text] [Related]
15. Time-dependent pharmacodynamics of amikacin on
Gibson JE; Nandanwar N; Neely MN
Microbiol Spectr; 2024 Feb; 12(2):e0322223. PubMed ID: 38236037
[No Abstract] [Full Text] [Related]
16. The timing of intravenous antibiotics and clinical outcomes of
Pang AH; Lin SW; Yang JH; Wang PH; Pan SW; Wei YF; Chen CY; Lee HS; Wu TS; Chang CH; Shu CC
Int J Tuberc Lung Dis; 2024 Feb; 28(2):73-80. PubMed ID: 38303039
[No Abstract] [Full Text] [Related]
17. Synergistic Efficacy of β-Lactam Combinations against
Story-Roller E; Maggioncalda EC; Lamichhane G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109979
[No Abstract] [Full Text] [Related]
18. No Amikacin, No Problem: a Successful Treatment Approach for Pediatric Otomastoiditis Due to Amikacin-Resistant Mycobacterium abscessus.
Richter WJ; Cohen KA
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685473
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous sputum conversion and reversion in Mycobacterium abscessus complex lung disease.
Jo KW; Park YE; Chong YP; Shim TS
PLoS One; 2020; 15(4):e0232161. PubMed ID: 32339194
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of pulmonary
Flight WG; Hough NE; Chapman SJ
Int J Mycobacteriol; 2020; 9(1):48-52. PubMed ID: 32474488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
